Base de dados : MEDLINE
Pesquisa : A16.710 [Categoria DeCS]
Referências encontradas : 44208 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 4421 ir para página                         

  1 / 44208 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29325266
[Au] Autor:Hu MN; Zhang Y; Zhao W
[Ad] Endereço:Department of Health Care, Haidian Maternal and Child Health Hospital, Beijing 100080, China.
[Ti] Título:[Analysis of 649 cases of stillbirth in third trimester].
[So] Source:Zhonghua Fu Chan Ke Za Zhi;52(12):822-827, 2017 Dec 25.
[Is] ISSN:0529-567X
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:To analyze the risk factors of stillbirth in third trimester. Clinical data of 649 cases of stillbirth in third trimester were analyzed retrospectively in 22 hospitals of Haidian district from October 2011 to September 2016, including the incidence, the maternal profile, the perinatal care during pregnancy and the causes of stillbirth. (1) The incidence of stillbirth in third trimester in Haidian district from October 2011 to September 2016 was 0.293%(649/221 845). While the incidence in floating pregnant women (0.349%, 342/97 939) was higher than that in the residence (0.248%, 307/123 906), with statistically significant difference (χ(2)=19.178, <0.01). The incidence of stillbirth in multiple pregnancy(0.201%, 89/4 264) was higher than that in singleton pregnancy (0.257%, 560/217 581), with statistically significant difference(χ(2)=4.690, <0.01). There was no statistically significant difference in the incidence of stillbirth between male (0.300%, 347/115 632) and female fetuses (0.284%, 302/106 205; χ(2)=0.467, >0.05).(2)Among the 649 cases, the floating population accounted for the majority of those who never had prenatal visit (84.0%, 21/25), or less than 5 visits (80.7%, 125/155), or the first visit was beyond 13 gestational weeks(66.0%, 165/649). The causes of stillbirth in order were fetal factors (30.7%, 199/649), maternal factors(28.0%, 182/649), umbilical cord factors (20.0%, 130/649), unexplained factors (17.6%, 114/649) and placental factors (3.7%, 24/649). Birth defects, pregnancy hypertensive disorders, umbilical cord entanglement or torsion were the most important factors, accounting for 22.8%(148/649), 17.4%(113/649), 17.3%(112/649), respectively. The floating pregnant women are key population of stillbirth in third trimester. Maternal care and education should be strengthened in this population. The prevention of birth defect, better prenatal care in women with complications, and close monitor during labor are the key measures to reduce the incidence of stillbirth in third trimester.
[Mh] Termos MeSH primário: Complicações na Gravidez/epidemiologia
Terceiro Trimestre da Gravidez
Natimorto/epidemiologia
[Mh] Termos MeSH secundário: Adulto
China/epidemiologia
Feminino
Feto
Seres Humanos
Placenta
Gravidez
Cuidado Pré-Natal
Estudos Retrospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180306
[Lr] Data última revisão:
180306
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180112
[St] Status:MEDLINE
[do] DOI:10.3760/cma.j.issn.0529-567x.2017.12.006


  2 / 44208 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28454692
[Au] Autor:Bustamante Helfrich B; Chilukuri N; He H; Cerda SR; Hong X; Wang G; Pearson C; Burd I; Wang X
[Ad] Endereço:Center on the Early Life Origins of Disease, Department of Population, Family and Reproductive Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States; Department of Clinical and Applied Science Education (Pathology), University of the Incarnate Word School of Osteopath
[Ti] Título:Maternal vascular malperfusion of the placental bed associated with hypertensive disorders in the Boston Birth Cohort.
[So] Source:Placenta;52:106-113, 2017 Apr.
[Is] ISSN:1532-3102
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: The associations of maternal conditions, before or during pregnancy, with placental lesions have not been adequately studied in populations. METHODS: In the Boston Birth Cohort, we evaluated associations between three maternal medical conditions (hypertensive disorders [HDs], gestational/pre-gestational diabetes and obesity), and placental histological findings, using a standardized classification system proposed by the Amsterdam Placental Workshop Group. Placental pathology diagnoses and clinical data from 3074 mothers with clinical indications who delivered singleton live births at the Boston Medical Center between October 1998 and November 2013 were evaluated. Associations between each maternal condition and maternal vascular malperfusion (MVM) of the placental bed and its standardized subgroups were examined using multivariate logistic and multinomial regressions. RESULTS: Women with HDs (chronic hypertension, eclampsia, preeclampsia, HELLP syndrome) had significantly increased odds of MVM lesions when compared to women with no HD (aOR 2.08 95% CI 1.74-2.50), after adjusting for demographics, substance use, diabetes and body mass index. No significant differences in frequencies or aORs were seen in women with and without diabetes, or across body mass index categories. Co-morbid condition patterns that included HDs were more likely to be associated with MVM than those without. DISCUSSION: Using a standardized classification system, we showed that MVM is strongly and specifically associated with maternal HDs, but not other maternal conditions. Additional studies are needed to confirm and validate our findings, and evaluate the role of maternal vascular lesions of the placental bed in relation to postnatal growth and development of the offspring and effect modifiers.
[Mh] Termos MeSH primário: Diabetes Gestacional/patologia
Hipertensão Induzida pela Gravidez/patologia
Obesidade/complicações
Placenta/irrigação sanguínea
Insuficiência Placentária/etiologia
[Mh] Termos MeSH secundário: Adulto
Índice de Massa Corporal
Feminino
Seres Humanos
Obesidade/patologia
Placenta/patologia
Insuficiência Placentária/patologia
Gravidez
Estudos Retrospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180307
[Lr] Data última revisão:
180307
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170430
[St] Status:MEDLINE


  3 / 44208 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29184401
[Au] Autor:Pillay P; Moodley K; Moodley J; Mackraj I
[Ad] Endereço:Discipline of Human Physiology, Nelson R Mandela School of Medicine, School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa.
[Ti] Título:Placenta-derived exosomes: potential biomarkers of preeclampsia.
[So] Source:Int J Nanomedicine;12:8009-8023, 2017.
[Is] ISSN:1178-2013
[Cp] País de publicação:New Zealand
[La] Idioma:eng
[Ab] Resumo:Preeclampsia remains a leading cause of maternal and fetal mortality, due to ineffective treatment and diagnostic strategies, compounded by the lack of clarity on the etiology of the disorder. Although several clinical and biological markers of preeclampsia have been evaluated, they have proven to be ineffective in providing a definitive diagnosis during the various stages of the disorder. Exosomes have emerged as ideal biomarkers of pathological states, such as cancer, and have more recently gained interest in pregnancy-related complications, due to their role in cellular communication in normal and complicated pregnancies. This occurs as a result of the specific placenta-derived exosomal molecular cargo, which may be involved in normal pregnancy-associated immunological events, such as the maintenance of maternal-fetal tolerance. This review provides perspectives on placenta-derived exosomes as possible biomarkers for the diagnosis/prognosis of preeclampsia. Using keywords, online databases were searched to identify relevant publications to review the potential use of placenta-derived exosomes as biomarkers of preeclampsia.
[Mh] Termos MeSH primário: Biomarcadores/análise
Exossomos/patologia
Placenta/citologia
Pré-Eclâmpsia/patologia
[Mh] Termos MeSH secundário: Feminino
Seres Humanos
Placenta/patologia
Pré-Eclâmpsia/diagnóstico
Gravidez
Prognóstico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Biomarkers)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171130
[St] Status:MEDLINE
[do] DOI:10.2147/IJN.S142732


  4 / 44208 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28454703
[Au] Autor:Starikov RS; Inman K; Has P; Iqbal SN; Coviello E; He M
[Ad] Endereço:Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, Women & Infants Hospital of Rhode Island, Providence, RI, USA; Phoenix Perinatal Associates, Phoenix, AZ, USA; Warren Alpert Medical School of Brown University, Providence, RI, USA.
[Ti] Título:Correlation of placental pathology and perinatal outcomes with Hemoglobin A1c in early pregnancy in gravidas with pregestational diabetes mellitus.
[So] Source:Placenta;52:94-99, 2017 Apr.
[Is] ISSN:1532-3102
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Data on the correlation among Hemoglobin A1c (HbA1c), placental pathology, and perinatal outcome in the pregestational diabetic population is severely lacking. We believe that this knowledge will enhance the management of pregnancies complicated by pregestational diabetes. We hypothesize that placental pathology correlates with glycemic control at an early gestational age. METHODS: This is a retrospective cohort study conducted from 2003 to 2011 at a large tertiary care center. Women included had a singleton gestation, preexisting diabetes mellitus, and information about delivery and placental pathology available for review. Placental pathology and perinatal outcomes were compared across three groups of patients with differing HbA1c levels (<6.5%, 6.5-8.4%, and ≥8.5%). RESULTS: 293 placentas were examined. HbA1c was measured at a mean of 9.5week gestation. Median HbA1c was 7.5%, interquartile range 6.5%-8.9%. 23% of the cohort had HbA1c <6.5%, 41.9% between 6.5% and 8.4%, and 34.8% > 8.5%. BMI varied significantly by group (35.4 vs. 34.4 vs. 32.0 respectively, P = 0.04). Individual placental lesions did not vary with HbA1c levels. The incidence of acute chorioamnionitis differed significantly in the type 1 population and "distal villous hypoplasia" varied in the type 2 population. DISCUSSION: The results show that HbA1c values in early pregnancy are poor predictors of future placental pathologies. As a result, HbA1c values obtained during early gestation (which reflect the level of glycemic control over an extended period of time) do not correlate with any particular placental pathology, despite reflecting the potential for placental insults secondary to pre-gestational diabetes.
[Mh] Termos MeSH primário: Glicemia
Diabetes Mellitus Tipo 1/patologia
Diabetes Mellitus Tipo 2/patologia
Hemoglobina A Glicada/análise
Placenta/patologia
Gravidez em Diabéticas/patologia
[Mh] Termos MeSH secundário: Adulto
Diabetes Mellitus Tipo 1/sangue
Diabetes Mellitus Tipo 2/sangue
Feminino
Seres Humanos
Gravidez
Resultado da Gravidez
Gravidez em Diabéticas/sangue
Estudos Retrospectivos
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Blood Glucose); 0 (Glycated Hemoglobin A); 0 (hemoglobin A1c protein, human)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170430
[St] Status:MEDLINE


  5 / 44208 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28454702
[Au] Autor:Ellery SJ; Della Gatta PA; Bruce CR; Kowalski GM; Davies-Tuck M; Mockler JC; Murthi P; Walker DW; Snow RJ; Dickinson H
[Ad] Endereço:The Ritchie Centre, Hudson Institute of Medical Research, Department of Obstetrics and Gynaecology, Monash University, Melbourne, Australia.
[Ti] Título:Creatine biosynthesis and transport by the term human placenta.
[So] Source:Placenta;52:86-93, 2017 Apr.
[Is] ISSN:1532-3102
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Creatine is an amino acid derivative that is involved in preserving ATP homeostasis. Previous studies suggest an important role for the creatine kinase circuit for placental ATP turnover. Creatine is obtained from both the diet and endogenous synthesis, usually along the renal-hepatic axis. However, some tissues with a high-energy demand have an inherent capacity to synthesise creatine. In this study, we determined if the term human placenta has the enzymatic machinary to synthesise creatine. METHODS: Eleven placentae were collected following elective term caesarean section. Samples from the 4 quadrants of each placenta were either fixed in formalin or frozen. qPCR was used to determine the mRNA expression of the creatine synthesising enzymes arginine:glycine amidinotransferase (AGAT) and guanidinoacetate methyltransferase (GAMT), and the creatine transporter (SLC6A8). Protein expression of AGAT and GAMT was quantified by Western blot, and observations of cell localisation of AGAT, GAMT and SLC6A8 made with immunohistochemistry. Synthesis of guanidinoacetate (GAA; creatine precursor) and creatine in placental homogenates was determined via GC-MS and HPLC, respectively. RESULTS: AGAT, GAMT and SLC6A8 mRNA and protein were detected in the human placenta. AGAT staining was identified in stromal and endothelial cells of the fetal capillaries. GAMT and SLC6A8 staining was localised to the syncytiotrophoblast of the fetal villi. Ex vivo, tissue homogenates produce both GAA (4.6 nmol mg protein h ) and creatine (52.8 nmol mg protein h ). DISCUSSION: The term human placenta has the capacity to synthesise creatine. These data present a new understanding of placental energy metabolism.
[Mh] Termos MeSH primário: Amidinotransferases/metabolismo
Creatina/metabolismo
Guanidinoacetato N-Metiltransferase/metabolismo
Proteínas de Membrana Transportadoras/metabolismo
Placenta/metabolismo
[Mh] Termos MeSH secundário: Transporte Biológico
Creatina/biossíntese
Células Endoteliais/metabolismo
Metabolismo Energético/fisiologia
Feminino
Seres Humanos
Gravidez
Células Estromais/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Membrane Transport Proteins); 0 (creatine transporter); EC 2.1.1.2 (GAMT protein, human); EC 2.1.1.2 (Guanidinoacetate N-Methyltransferase); EC 2.1.4.- (Amidinotransferases); EC 2.1.4.1 (glycine amidinotransferase); MU72812GK0 (Creatine)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170430
[St] Status:MEDLINE


  6 / 44208 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28454701
[Au] Autor:Gunel T; Hosseini MK; Gumusoglu E; Kisakesen HI; Benian A; Aydinli K
[Ad] Endereço:Istanbul University, Faculty of Science, Department of Molecular Biology and Genetics, Istanbul, Turkey. Electronic address: gunel@istanbul.edu.tr.
[Ti] Título:Expression profiling of maternal plasma and placenta microRNAs in preeclamptic pregnancies by microarray technology.
[So] Source:Placenta;52:77-85, 2017 Apr.
[Is] ISSN:1532-3102
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Preeclampsia (PE) is one of the leading causes of maternal and fetal morbidity and mortality, occurring usually in the second half of pregnancy and affecting approximately 5-8% of pregnancies in the world. miRNAs play critical role in the regulation of placental development processes. We aimed to determine specific novel miRNAs for early diagnosis of preeclampsia which is one of the most dangerous pregnancy diseases. In this study 72 samples, maternal age 22 ≤ and ≤36, have been analyzed; maternal plasma and placental miRNAs were isolated from 18 severe preeclampsia (sPE) patients and 18 controls, respectively. Profiling of human miRNAs (1368 probe) was performed in samples with Agilent v16 microarrays for detection of the differences in miRNA expression between two groups. The results were validated by using TaqMan RT-qPCR method. The analysis indicated that 406 of these miRNAs in all placentas and 42 of these miRNAs in all maternal plasma were expressed. The relative expression analysis has shown that 12 miRNAs (p < 0.05 and >2-fold) in maternal plasma were differentially expressed in PE and control group. However, five miRNAs were validated by qRT-PCR. Once validated miRNAs have been searched in databases for their target genes and function, it has been shown that there are some preeclampsia related pathways as a target such as angiogenesis, cardiovascular, hypertension, placental abruption and preeclampsia disorders. Differentially expressed and validated plasma miRNAs might be used as notable biomarkers for non-invasive early diagnosis of preeclampsia and treatment of disease.
[Mh] Termos MeSH primário: Perfilação da Expressão Gênica/métodos
MicroRNAs/metabolismo
Placenta/metabolismo
Pré-Eclâmpsia/metabolismo
[Mh] Termos MeSH secundário: Adulto
Feminino
Seres Humanos
MicroRNAs/sangue
MicroRNAs/genética
Análise em Microsséries
Pré-Eclâmpsia/sangue
Pré-Eclâmpsia/genética
Gravidez
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (MicroRNAs)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170430
[St] Status:MEDLINE


  7 / 44208 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28454700
[Au] Autor:Akkermans J; de Vries SM; Zhao D; Peeters SHP; Klumper FJ; Middeldorp JM; Oepkes D; Slaghekke F; Lopriore E
[Ad] Endereço:Department of Obstetrics, Leiden University Medical Center, Leiden, The Netherlands. Electronic address: j.akkermans@lumc.nl.
[Ti] Título:What is the impact of placental tissue damage after laser surgery for twin-twin transfusion syndrome? A secondary analysis of the Solomon trial.
[So] Source:Placenta;52:71-76, 2017 Apr.
[Is] ISSN:1532-3102
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The introduction of the Solomon technique for the treatment of twin-twin transfusion syndrome (TTTS) increased placental exposure to laser energy. This study aims to identify the impact of power and energy used in laser treatment on placental tissue and pregnancy outcome. METHODS: Pictures of all dye-injected placentas since the start of the Solomon trial were analyzed. Placental damage was scored using a grading system including visual scar depth and affected proportion of the vascular equator. Parameters analyzed included laser power and total energy, gestational age (GA) at laser, GA at birth, laser-to-delivery interval and preterm prelabor rupture of membranes (PPROM). RESULTS: We included 122 cases in the analysis. More placental damage occurred more often in the Solomon group (42%) compared to the selective group (15%) (p < 0.001). In multivariate analysis, more placental damage was associated with higher laser energy (regression coefficient B 0.002) but not with higher power setting (regression coefficient B -0.442). More damage was associated with earlier GA at birth (regression coefficient B -0.167), higher incidence of PPROM <32 weeks (regression coefficient B 0.003) and a shorter laser-to-delivery interval (regression coefficient B -0.168). CONCLUSIONS: Placental damage is positively associated with more laser energy but negatively associated with higher power setting. More placental damage was associated with a lower GA at birth, shorter laser-to-delivery interval and higher PPROM rate. Whether these results should lead to a change in surgical technique requires more research, both further ex-vivo experiments on human placentas and clinical studies.
[Mh] Termos MeSH primário: Transfusão Feto-Fetal/cirurgia
Complicações Intraoperatórias/patologia
Terapia a Laser/efeitos adversos
Placenta/cirurgia
[Mh] Termos MeSH secundário: Adulto
Feminino
Transfusão Feto-Fetal/patologia
Seres Humanos
Placenta/irrigação sanguínea
Placenta/patologia
Gravidez
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170430
[St] Status:MEDLINE


  8 / 44208 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28454699
[Au] Autor:Murthi P; Wallace EM; Walker DW
[Ad] Endereço:Department of Medicine, School of Clinical Sciences, Monash University, Monash Medical Centre, Clayton, Victoria, 3168, Australia; The Ritchie Centre, Hudson Institute of Medical Research, 27-31 Wright St., Clayton, Victoria, 3168, Australia.
[Ti] Título:Altered placental tryptophan metabolic pathway in human fetal growth restriction.
[So] Source:Placenta;52:62-70, 2017 Apr.
[Is] ISSN:1532-3102
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Tryptophan is a substrate for kynurenine pathway metabolism in the placenta. We investigated if kynurenine metabolites change over gestation, if they are different between pregnancies with normal and fetal growth restriction (FGR), and if the oxygen environment modulated kynurenine pathway activity in the human placenta. METHODS: Tryptophan, kynurenine, and downstream kynurenine metabolites were determined in maternal venous blood, umbilical cord blood, and placental samples obtained in 1st and 3rd trimester pregnancies including FGR, and in the media of placental explants incubated with 20% or 5-8% O for 24, 48 or 72 h. RESULTS: All the major kynurenine metabolites were present in cord blood, and in general were higher than in maternal blood. IDO and TDO mRNA and protein expression, responsible for kynurenine production from tryptophan, were significantly lower in placentas from FGR pregnancies compared with control. Explants prepared from 1st and 3rd trimester placentas actively produced all the major kynurenine pathway metabolites which, together with expression of IDO, TDO, KYN-OHase and 3HAO mRNAs, were significantly lower after 24 h exposure to 5-8% O compared to 20% O CONCLUSIONS: Expression and activity of the kynurenine pathway is present in the placenta from early gestation, and is down-regulated by hypoxia and in FGR pregnancies.
[Mh] Termos MeSH primário: Retardo do Crescimento Fetal/metabolismo
Redes e Vias Metabólicas/fisiologia
Placenta/metabolismo
Triptofano/metabolismo
[Mh] Termos MeSH secundário: Adulto
Feminino
Sangue Fetal/metabolismo
Seres Humanos
Cinurenina/metabolismo
Gravidez
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
343-65-7 (Kynurenine); 8DUH1N11BX (Tryptophan)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170430
[St] Status:MEDLINE


  9 / 44208 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28454697
[Au] Autor:Tian FY; Hivert MF; Wen X; Xie C; Niu Z; Fan L; Gillman MW; Chen WQ
[Ad] Endereço:Department of Medical Statistics and Epidemiology, Guangzhou Key Laboratory of Environmental Pollution and Health Assessment, Guangdong Provincial Key Laboratory of Food, Nutrition and Health, School of Public Health, Sun Yat-sen University, Guangzhou, Guangdong, China. Electronic address: tianfy@ma
[Ti] Título:Tissue differences in DNA methylation changes at AHRR in full term low birth weight in maternal blood, placenta and cord blood in Chinese.
[So] Source:Placenta;52:49-57, 2017 Apr.
[Is] ISSN:1532-3102
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Very few study addressed the relationship between Aryl-hydrocarbon receptor repressor (AHRR) DNA methylation and low birth weight, especially in multiple tissues of mother-infant pairs. In this study, we aimed to investigate AHRR DNA methylation modification in cord blood, placenta and maternal blood between full term low birth weight (FT-LBW) and full term normal birth weight (FT-NBW) newborns. METHODS: We enrolled 90 FT-LBW and 90 FT-NBW mother-infant pairs, of which all placenta and cord blood samples were collected while 45 maternal blood samples of each group were collected. We measured AHRR DNA methylation (Chr5: 373013-373606) using Sequenom MassARRAY, and assessed associations between AHRR DNA methylation and FT-LBW using logistic regression adjusting for maternal age, education, family income, delivery mode, and passive smoking. RESULTS: FT-LBW babies had 3% lower methylation at Chr5: 373378 (CpG 13) in cord blood, and 4-9% higher methylation levels at Chr5: 373315, 373378, 373423, 373476 and 373490/373494 (CpG 10; 13; 15; 16; 17/18 respectively) in maternal blood, comparing with FT-NBW. The methylation of Chr5: 373378 (CpG 13) remained significant association with FT-LBW both in cord blood (OR = 0.90; 95% CI: 0.82, 0.98) and maternal blood (OR = 1.14; 95% CI: 1.04, 1.25) further adjusting for each other in the same model. We observed no significant difference at any CpG sites in placenta. DISCUSSION: AHRR DNA methylation of cord and maternal blood might be independently associated with FT-LBW in different ways.
[Mh] Termos MeSH primário: Fatores de Transcrição Hélice-Alça-Hélice Básicos/metabolismo
Metilação de DNA
Sangue Fetal/metabolismo
Recém-Nascido de Baixo Peso/metabolismo
Placenta/metabolismo
Proteínas Repressoras/metabolismo
[Mh] Termos MeSH secundário: Fatores de Transcrição Hélice-Alça-Hélice Básicos/genética
Estudos de Casos e Controles
China
Feminino
Seres Humanos
Recém-Nascido
Idade Materna
Gravidez
Proteínas Repressoras/genética
Poluição por Fumaça de Tabaco
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (AHRR protein, human); 0 (Basic Helix-Loop-Helix Transcription Factors); 0 (Repressor Proteins); 0 (Tobacco Smoke Pollution)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170430
[St] Status:MEDLINE


  10 / 44208 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28454695
[Au] Autor:Hu TX; Guo X; Wang G; Gao L; He P; Xia Y; Gu H; Ni X
[Ad] Endereço:Department of Physiology, Second Military Medical University, Shanghai, China; No.117 Hospital of PLA, Hangzhou, China.
[Ti] Título:MiR133b is involved in endogenous hydrogen sulfide suppression of sFlt-1 production in human placenta.
[So] Source:Placenta;52:33-40, 2017 Apr.
[Is] ISSN:1532-3102
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Increased production of soluble fms-like tyrosine kinase-1 (sFlt-1) from placenta is one of the major contributors to the development of preeclampsia. Our previous study has shown that hydrogen sulfide (H S) inhibits sFlt-1 release in placenta. In the present study, we sought to investigate whether endogenous H S affects sFlt-1 production and elucidate which H S-producing enzyme is responsible for its effect in placenta. It was found that, besides cystathionine ß-synthase (CBS) and cystathionine γ-lyase (CSE), 3-mercaptopyruvatesulfurtransferase (3-MST) was identified in human placenta and mainly localized in syncytiotrophoblasts. There was no significant difference in expression level of 3-MST among preeclamptic and normal placentas. Treatment of cultured syncytiotrophoblasts with NaHS and l-cysteine suppressed sFlt-1 mRNA expression and caused a decrease in sFlt-1 protein content in culture media of the cells. Transfection of syncytiotrophoblasts with CBS siRNA and CSE siRNA reversed the above effects of l-cysteine. Furthermore, NaHS and l-cysteine treatment decreased the half-life of sFlt-1 mRNA and increased the expression of miR-133b targeting sFlt-1. MiR-133b expression was downregulated in preeclamptic placentas and correlated with the level of CBS and CSE. These results indicate that H S is an important regulatory factor in sFlt-1 production in placenta. Reduced H S generation in placenta contributes to development of preeclampsia by enhancing sFlt-1 production.
[Mh] Termos MeSH primário: Sulfeto de Hidrogênio/metabolismo
MicroRNAs/metabolismo
Placenta/metabolismo
Receptor 1 de Fatores de Crescimento do Endotélio Vascular/metabolismo
[Mh] Termos MeSH secundário: Células Cultivadas
Cistationina beta-Sintase/metabolismo
Cistationina gama-Liase/metabolismo
Cisteína/farmacologia
Regulação para Baixo
Feminino
Seres Humanos
Sulfeto de Hidrogênio/farmacologia
Gravidez
Sulfurtransferases/metabolismo
Trofoblastos/efeitos dos fármacos
Trofoblastos/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (MIRN133 microRNA, human); 0 (MicroRNAs); EC 2.7.10.1 (FLT1 protein, human); EC 2.7.10.1 (Vascular Endothelial Growth Factor Receptor-1); EC 2.8.1.- (Sulfurtransferases); EC 2.8.1.2 (3-mercaptopyruvate sulphurtransferase); EC 4.2.1.22 (Cystathionine beta-Synthase); EC 4.4.1.1 (Cystathionine gamma-Lyase); K848JZ4886 (Cysteine); YY9FVM7NSN (Hydrogen Sulfide)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170430
[St] Status:MEDLINE



página 1 de 4421 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde